Propanc Biopharma Announces Publication Of Evaluation Of Recombinant Trypsinogen And Chymotrypsinogen In Peer-Reviewed Journal Microbial Cell Factories
Propanc Biopharma Inc PPCB
$1.01
▼ -2.88%
($-0.03)
🎈 Low Float
🎢 High Beta
Open
$1.07
Prev Close
$1.04
Day Range
$0.95 – $1.08
52W Range
$0.95 – $270.25
Market Cap
$3.54M
Beta
3.18
EPS (TTM)
$-25.66
📋 Company Profile
| Industry | Biotechnology |
| Country | AU |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2012-06-15 |
| Shares Out. | 2,280,000 |
| Website | propanc.com/ ↗ |
| Phone | 13023513367 |
| Employees | 2 |
| Net Income | -$6.4M |
| Free Cash Flow | -$4.1M |
| Total Assets | $14.3M |
| Total Liabilities | $3.5M |
| Equity | $9.8M |
About Propanc Biopharma Inc
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Propanc Biopharma Inc is a publicly traded company under the ticker symbol PPCB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.